Anene B M, Ross C A, Anika S M, Chukwu C C
Faculty of Veterinary Medicine, University of Nigeria, Nsukka, Nigeria.
Vet Parasitol. 1996 Mar;62(1-2):43-50. doi: 10.1016/0304-4017(95)00856-x.
A study was conducted in vitro to assess the ability of calcium antagonists to reverse trypanocidal resistance in Trypanosoma evansi. Susceptibility patterns of sensitive and resistant parasites were evaluated against calcium antagonists of several chemical classes (verapamil, cyproheptidine, desipramine and chlopromazine), alone and in combination with suramin, diminazene aceturate or melarsen oxide cyteamine. The putative resistance modulators were intrinsically antitrypanosomal, but were unable to reverse resistance to any of the trypanocides tested. It was thus concluded that resistance to these trypanocides in T. evansi may differ from drug resistance mechanisms occurring in cancer cells, malaria or in South American trypanosomosis, where calcium antagonists have successfully reversed resistance.
进行了一项体外研究，以评估钙拮抗剂逆转伊氏锥虫对杀锥虫药物耐药性的能力。针对几种化学类别的钙拮抗剂（维拉帕米、赛庚啶、地昔帕明和氯丙嗪），单独以及与苏拉明、乙酰氨基阿苯达唑或美拉胂醇半胱胺联合使用，评估了敏感和耐药寄生虫的敏感性模式。假定的耐药性调节剂本身具有抗锥虫活性，但无法逆转对所测试的任何一种杀锥虫药物的耐药性。因此得出结论，伊氏锥虫对这些杀锥虫药物的耐药性可能与癌细胞、疟疾或南美锥虫病中出现的耐药机制不同，在这些疾病中钙拮抗剂已成功逆转耐药性。
